跳至主要内容
临床试验/CTRI/2024/08/072972
CTRI/2024/08/072972尚未招募3 期

A RANDOMIZED CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF TRIPHALADI KASHAYAM ON MICROALBUMINURIA LEVELS IN TYPE II DIABETES MELLITUS (MADHUMEHA)

Payal Durge1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年9月3日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Reduction in Microalbuminuria levels

研究概览

简要总结

India ranks top amongst diabetic sufferers. 8.5% of adults aged 18 years and older had Diabetes mellitus**.** Indian prevalence of diabetic nephropathy ranges from 0.9% to 62%. 10 years after diagnosis of DM the prevalence rate is 25%. In Chennai Urban Rural Epidemiology Study (CURES) people with a history of diabetes had a higher prevalence rate of microalbuminuria and Diabetic Nephropathy.In the survey of National Health and Nutrition Examination Survey (NHANES) and Kidney Early Evaluation Program only 9% of patient were aware of Diabetic Nephropathy and DKD (Diabetic Kidney Disease). A 12 years observational study reported that 44% of people with Type 2 DM developed proteinuria during follow up. Prameha is a disease involving Tridosha as well as all the Dhatus such as Meda, Rasa, Rakta, Mamsa, Vasa, Lasika, Majja, Shukra and Ojas (except Asthi Dhatu). Mainly Kapha Dosha and Meda Dhatu involves in the Samprapti of Prameha. If Prameha is untreated for long period of time it converts in to Madhumeha. Type II DM caused by insulin antagonism can be correlated with Avaran Janya Madhumeha. Microalbuminuria pathology starts with glycation of efferent arteriole. In samprapti of Prameha,Dushti of Kapha dosha leads to all Dhatu Dushti, Bahu Drava Kapha afflicts Meda dhatu. Kapha along with Meda Dhatu creates Avaran and develops Dhatu Shaithilya. Therefore glycation can be compared with Kapha and Meda janya Avaran.In Contemporary medicine Antihypertensive drugs are employed for treatment of microalbuminuria therefore patient should depend on both Anti-hypertensive and Anti-diabetic drugs. Here we are exploring single medication which target both diabetes as well as Microalbuminuria. According to the Study,the diabetic rats treated with Aragwadadi Kashayam at the dose level 200 and 400 mg/kg showed significant (p<0.001) decrease in Microalbuminuria levels,FBS, PPBS.A study concluded that a significant improvement was observed in Microalbuminuria level,fasting blood sugar level and post prandial glycemic level, and reported reduction in excessive urination of patients treated with Aragwadhadi kashayam.Aragwadhadi Kashayam is much effective in improving kidney function and preventing progression of diabetic nephropathy.Various formulation have been described in ayurveda classics which are having effect on Madhumeha and Triphaladi Kashayam is one of them.For treatment of microalbuminuria and Avaranjanya Madhumeha drug should have the properties of Kapha Medo Haram ,Kleda shoshanam, Agnideepan, Amapachana and Rukshanam. Triphaladi Kashayam is a formulation which contains Triphala (Amalaki,Vibhitaki, Haritaki) ,Aragwadha and Draksha having all this properties.So it is hypothesized that it will act in breaking down the samprapti of madhumeha and microalbuminuria.

Hence this work entitled "A RANDOMISED CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF TRIPHALADI KASHAYAM ON MICROALBUMINURIA LEVELS IN TYPE II DIABETES MELLITUS*(MADHUMEHA*” is planned.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • H/O Type II Diabetes Mellitus Microalbuminuria levels between 30 to 299 mg/dl HbA1c more than 6.5%.

排除标准

  • Patient with Age below 18 and above 75 years Patient with H/O Type 1 DM Type II DM on insulin therapy Type II DM along with hypertension and under Anti-hypertensive Medication Microalbuminuria levels more than 300 mg/dl Pregnant and lactating mothers Microalbuminuria induced due to other diseases – Pregnancy, CKD Patient with other complication of DM–Ketoacidosis, Diabetic nephropathy Any other Systemic illness.

结局指标

主要结局

Reduction in Microalbuminuria levels

时间窗: criteria will be assessed on 31st days

次要结局

  • Reduction in FBS and PPBS levels(Reduction in symptoms like Prabhoot Mutrata)

研究者

发起方
Payal Durge
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Payal Durge

Sri Jayendra Saraswathi Ayurveda College and Hospital

研究点 (1)

Loading locations...

相似试验